SLRX vs ZTS · $4.9M cap vs P/E 25, rev $2.47B
Salarius Pharmaceuticals Inc (SLRX) versus Zoetis Inc (ZTS) — a side-by-side from cached financials, not a winner call.
Salarius Pharmaceuticals Inc (SLRX) is a biotechnology company listed on NASDAQ.
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported SLRX revenue for 2023-03-31 was $0. Net income was -$5.3M. SLRX currently screens at market cap $4.9M.
Latest reported ZTS revenue for 2026-06-30 was $2.47B. Net income was $691.0M. Revenue was up 9.1% from 2026-03-31 to 2026-06-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
SLRX currently screens at market cap $4.9M. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
Not investment advice. Open the SLRX and ZTS stock pages for the full models.
Not investment advice.